Taken together, these findings are clinically exciting, as it suggests that substance P-antagonist based therapies may be able to directly improve right ventricular parameters above simply relieving right ventricular afterload for PAH treatment. This evidence concerns the gene TAC1 and pulmonary arterial hypertension.